In this work, Cloupharm has been involved in the discovery of four compounds through a virtual screening procedure as putative sterol 14α-demethylase (CYP51) Candida albicans inhibitors. The compounds had the ability to inhibit growth of C. albicans cells and one was highly selective on C. albicans CYP51 which did not exhibit cytotoxic effects on cells isolated from liver. These compounds may serve as new leads for the treatment of candidiasis.

ChemMedChem. 2018 Feb 6;13(3):251-258. doi: 10.1002/cmdc.201700602. Epub 2018 Jan 26.